Optic Nerve Sheath Biomarker for Intracranial Pressure Prediction

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods lack effective biomarkers to predict the risk of Visual Impairment and Intracranial Pressure (VIIP) syndrome in astronauts exposed to microgravity, which is characterized by ophthalmic abnormalities such as optic disc edema and elevated intracranial pressure.

Innovation Solution

The method involves administering artificial cerebrospinal fluid (CSF) via intrathecal infusion, measuring CSF pressure and optic nerve sheath (ONS) diameter, and calculating the ONS diameter/CSF pressure ratio to determine the risk of developing VIIP syndrome, with specific thresholds indicating susceptibility.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If no biomarker prediction method is used, then all astronauts are treated equally regarding microgravity exposure risk, but this results in inability to identify individuals susceptible to VIIP syndrome

Engineering Contradiction:
Improverisk prediction accuracyVSAvoidtesting procedure complexity
Core Design Contradiction:
Measurement precisionVSDevice complexity

Solution Approach 1:

The patent performs preliminary testing of optic nerve sheath response to CSF pressure changes before spaceflight missions. By conducting intrathecal infusions and measurements during ground-based preparation, the system identifies susceptible individuals beforehand, enabling preventive measures to be taken before actual microgravity exposure occurs.

Inventive Principle:
Principle #10Preliminary action

Solution Approach 2:

The patent uses the optic nerve sheath as an intermediary structure to indirectly assess intracranial pressure susceptibility. Instead of directly measuring ICP response to microgravity, the system measures ONS diameter changes in response to controlled CSF pressure variations, providing a surrogate biomarker for predicting VIIP syndrome risk.

Inventive Principle:
Principle #24Intermediary (Mediator)

2Reliability

If intrathecal infusion testing is performed to measure ONS response to CSF pressure, then predictive biomarker data is obtained, but this increases procedural complexity and invasiveness

Engineering Contradiction:
ImproveVIIP risk prediction reliabilityVSAvoidinfusion device complexity
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The intrathecal infusion device is designed to perform multiple functions: it administers controlled CSF volume increments, measures resulting CSF pressure changes, and monitors optic nerve sheath diameter responses. This multi-functional approach consolidates what could be separate testing procedures into a single integrated system, reducing overall complexity while maintaining prediction reliability.

Inventive Principle:
Principle #6Universality (Multi-functionality)

3Measurement precision

If multiple CSF pressure measurements are taken during intermittent infusions, then accurate ONS response data is obtained, but this increases measurement time and procedural duration

Engineering Contradiction:
ImproveCSF pressure measurement precisionVSAvoidtesting duration
Core Design Contradiction:
Measurement precisionVSLoss of time

Solution Approach 1:

The testing protocol uses periodic intermittent infusions rather than continuous infusion, with CSF volume administered in discrete increments (e.g., 0.5 mL steps). Measurements are taken at regular intervals after each infusion increment, allowing the system to capture the ONS response curve over time while maintaining manageable testing duration through structured periodic sampling.

Inventive Principle:
Principle #19Periodic action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach allows for the identification of individuals at risk of VIIP syndrome by correlating inter-individual changes in ONS response to CSF pressure alterations, providing predictive biomarkers for mitigating the risks associated with microgravity exposure.

Implementation Method 1

measuring the optic nerve sheath (ONS) diameter in the subject following each intermittent CSF administration

Methodology Applied
Scientific EffectMechanical deformation: Deformation

Data Source

PatentUS10980437B2Biomarkers for visual impairment and intracranial pressure (VIIP) syndrome
Publication Date: 2021.04.20 P&X MEDICAL NV

AI summary

Described herein is the use of the optic nerve sheath (ONS) response to alterations in cerebrospinal fluid (CSF) pressure for predicting the risk of developing Visual Impairment and Intracranial Pressure (VIIP) syndrome in a subject.